Compare BPYPO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPYPO | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | Bermuda | United States |
| Employees | 30200 | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | BPYPO | VCEL |
|---|---|---|
| Price | $14.50 | $36.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $60.40 |
| AVG Volume (30 Days) | N/A | ★ 592.9K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $148.17 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | N/A | $29.24 |
| 52 Week High | N/A | $63.00 |
| Indicator | BPYPO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 45.31 |
| Support Level | $14.20 | $35.85 |
| Resistance Level | $14.52 | $42.68 |
| Average True Range (ATR) | 0.21 | 1.63 |
| MACD | 0.01 | -0.32 |
| Stochastic Oscillator | 51.85 | 12.60 |
Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.